# US 2012/0251441 A1 · Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251441 A1
- Document ID: US20120251441A1
- Status: Published application
- Kind: A1
- Application number: 13/516,628
- Filed: 2009-12-15
- Published: 2012-10-04
- Earliest claimed: 2009-12-15
- Inventors: Iseu da Silva Nunes
- Web page: https://patentgrep.com/patent/US20120251441A1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for chronic systemic diseases such as cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.

## Claims

### Claim 1

An adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments characterized as an association or combination of substances for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, including a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use, or in drug formulations with at least one other pharmacologically active compound or substance and/or non-drug treatments. The referred pharmacologically active substances or compounds can be selected among the main classes or categories, cited here for illustrative purposes only and by no means constituting an exhaustive list: Alkylating agents, such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) polyunsaturated fatty acids or Pufas (eicosaminopentoic acid—EPA, linoleic acid docosahexanenoic acid—DHA), aminoacids (arginine, glutamine), steroids (megestrol acetate), steroidal anti-inflammatory drugs (hydrocortisone, cortisone, corticosterone, dexamethasone, betamethasone, prednisolone, prednisone, methylprednisolone, budesonide, beclomethasone), derivatives of tetrahydrocannabinol (dronabinol), non-steroidal anti-inflammatory drugs (ibuprofen), enzyme inhibitors (eicosapentaenoic acid, hydrazine sulfate), hormones (melatonin, somatropin) and others, and non-drug treatments can be selected among the following classes or categories, cited as exemplification and by no means constituting an exhaustive list: surgical procedures (surgery, cryosurgery, electrocauterization, surgery associated to polarized light or laser with the use of photosensitizing substances, endoscopic radiofrequency ablation with the use of balloon catheter, removal of lesions by chemical abrasion, transplantation of bone marrow cells and stem cells, systemic and localized radiotherapy) and other compounds or substances not specified. All the classes or categories of pharmacologically active substances and/or classes or categories of non-drug treatments can be selected for use in the present invention, alone or in combination or association with each other.

### Claim 2 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized by the referred treatments that include the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) defined in the state of the art as a proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride, with molecular weight of 320.000 Dalton (320 kDa), that in chemical analyses has shown the presence of 11.6±4.0% of total lipids, 22.7±5.0% of palmitoleic acid, 42.9±2.0% of linoleic acid and 32.0±3.0% of oxidated linoleic acid, 20.1±0.9% of magnesium ions, 10.0±3.3% of ammonium ions, 45.2±2.7% of phosphate and 0.49±0.01% of proteins; the aminoacid distribution in the protein is: Asp 7.19%; Thr 3.56%; Ser 7.56%; Glu 8.53%; Pro 0.5%; Gly 9.69%; Ala 7.46%; Val 1.0%; Met 4.38%, Isoleu 2.54%, Leu 3.03%, Tyr 0.5%, Phe 1.0%, His 2.83%; Lys 3.56%, Trp 1.3% and Arg 35.2%.

### Claim 3 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances aimed for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or at least one other pharmacologically active compound or substance. These other compounds or substances can be selected among the following classes or categories, cited as exemplification and by no means constituting an exhaustive list: Alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase), which can be used alone or combined or associated with each other.

### Claim 4 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer that shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one non-drug treatment, and these non-drug treatments can be selected among the following classes or categories cited as exemplification and by no means constituting an exhaustive list: surgical procedures (surgery, cryosurgery, electrocauterization, surgery associated to polarized light or laser with the use of photosensitizing substances, endoscopic radiofrequency ablation with the use of balloon catheter, removal of lesions by chemical abrasion, transplantation of bone marrow cells and stem cells, systemic and localized radiotherapy) and others, which can be used alone or in combination or association with each other.

### Claim 5 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, and specifically the treatment of precancerous lesions of any degree, that is, dysplasias and/or internal or gastroesophageal epithelial metaplasias, or else, precancerous lesions of any degree such as lesions or dysplasias associated to gastroesophageal reflux disease or GERD, epithelial lesions or dysplasias or metaplasias called Barrett's syndrome or esophagus, caused or associated to the carcinogenic action of chemical compounds and other aggressive agents, that shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other pharmacologically active compound or substance. These compounds or substances can be selected among the following classes or categories cited as exemplification, and by no means constituting an exhaustive list: antacids (aluminum hydroxide and magnesium hydroxide and others), H2 blockers (famotidine, cimetidine, ranitidine and others), proton pump inhibitors (omeprazol, esomeprazol, lansoprazol, pantoprazol, rabeprazol and others), prokinetics (metoclopramide, domperidone, cisapride and others) and mucosal protectors (sucralfate and others), and other compounds not specified, which can be used alone or in combinations or associations with each other.

### Claim 6 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1 characterized as an association or combination of substances for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, and specifically for the treatment of precancerous lesions of any degree, that is, dysplasias and/or internal or gastroesophageal epithelial metaplasias, that is, precancerous lesions of any degree such as injuries or dysplasias associated to the gastroesophageal reflux disease or GERD, epithelial lesions or dysplasias or metaplasias called Barrett's syndrome or esophagus caused or associated to the carcinogenic action of chemical compounds and other aggressive agents that shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance. These compounds or substances can be selected among the following classes or categories, cited as exemplification and by no means constituting an exhaustive list: antacids (aluminum hydroxide and magnesium hydroxide and others), H2 blockers (famotidine, cimetidine, ranitidine and others), proton pump inhibitors (omeprazol, esomeprazol, lansoprazol, pantoprazol, rabeprazol and others), prokinetics (metoclopramide, domperidone, cisapride and others), mucosal protectors (sucralfate and others) and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 7 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or internal or gastroesophageal epithelial metaplasias associated to the gastroesophageal reflux disease or GERD, caused or associated to the carcinogenic action of chemical compounds and other aggressive agents, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other non-drug treatment. These non-drug treatments can be selected among the following classes or categories, cited as exemplification, and by no means constituting an exhaustive list: surgical procedures (surgery to correct the hiatal hernia, cryotherapy using carbon dioxide or liquid nitrogen, esophageal endoscopic mucosal resection, endoscopic radiofrequency ablation using balloon catheter, electrocauterization, electrocauterization, surgery associated to polarized light or laser with the use of photosensitizing substances) and other treatments not specified, which can be used alone or in combination or association with each other.

### Claim 8 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association of combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically for the treatment of precancerous lesions of any degree, that is, dysplasias and/or internal or gastroesophageal epithelial metaplasias associated to the gastroesophageal reflux disease or GERD, caused or associated to the carcinogenic action of chemical compounds and other aggressive agents, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with other non-drug and drug treatments. The referred non-drug treatments can be selected among the following classes or categories: surgical procedures (surgery to correct the hiatal hernia, cryotherapy using carbon dioxide or liquid nitrogen, esophageal endoscopic mucosal resection, endoscopic radiofrequency ablation using balloon catheter, electrocauterization, electrocauterization, surgery associated to polarized light or laser with the use of photosensitizing substances) and other treatments not specified. These drug treatments can be selected among the following classes or categories: antacids (aluminum hydroxide and magnesium hydroxide and others), H2 blockers (famotidine, cimetidine, ranitidine and others), proton pump inhibitors (omeprazol, esomeprazol, lansoprazol, pantoprazol, rabeprazol and others), prokinetics (metoclopramide, domperidone, cisapride and others), mucosal protectors (sucralfate and others) and other compounds not specified, which can be used or in combination or association with each other.

### Claim 9 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias, that is, precancerous skin lesions of any degree, such as actinic keratosis and others, associated to the action of external aggressive and/or carcinogenic agents, such as solar radiation, which shall include the a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one pharmacologically active compound or substance. These compounds or substances can be selected among the following classes or categories, cited as exemplification, and by no means constituting an exhaustive list: cytotoxic compounds (5-Fluorouacil-5 FU), photosensitizing agents (5-aminolevulinic acid 5-ALA), biological response modifiers (imiquimimod, resiquimod), monoclonal antibodies conjugated to phototherapeutic agents and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 10 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias, that is, precancerous skin lesions of any degree, such as actinic keratosis and others, associated to the action of external aggressive and/or carcinogenic agents, such as solar radiation, which shall include the a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other non-drug treatment. These non-drug treatments can be selected among the following classes or categories, being cited for exemplification only, and by no means constituting an exhaustive list: localized radiotherapy, cryosurgery, electrocauterization, removal of lesions by chemical abrasion and other procedures not specified, which can be used alone or in combination or association with each other.

### Claim 11 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias, that is, precancerous skin lesions of any degree, such as actinic keratosis and others, associated to the action of external aggressive and/or carcinogenic agents, such as solar radiation, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component that can be used in clinical practice with other prior, concomitant and subsequent non-drug and drug treatments. These other non-drug treatments can be selected among the following classes or categories: localized radiotherapy, cryosurgery, electrocauterization, removal of lesions by chemical abrasion and other procedures not specified, and the other drug treatments can be selected among the following classes or categories: cytotoxic compounds (5-Fluorouacil-5 FU), photosensitizing agents (5-aminolevulinic acid 5-ALA), biological response modifiers (imiquimimod, resiquimod), monoclonal antibodies conjugated to phototherapeutic agents, and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 12 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias associated to the several types of human papilloma virus (HPV) that shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other pharmacologically active compound or substance. These compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: biological response modifiers (imiquimod, resiquimod), HPV vaccines, photoactive compounds and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 13 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias associated to the several types of human papilloma virus (HPV) that shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance. These other compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: biological response modifiers (imiquimod, resiquimod), HPV vaccines, photoactive compounds and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 14 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias associated to the several types of human papilloma virus (HPV) that shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other non-drug treatment. These other non-drug treatments can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: surgical methods (surgical removal, cryosurgery, electrocauterization, conization, scraping, scooping (curettage), removal of lesions by chemical abrasion) and other procedures not specified, which can be used alone or in combination of association with each other.

### Claim 15 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of precancerous lesions of any degree, that is, dysplasias and/or epithelial metaplasias associated to the several types of human papilloma virus (HPV) that shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use with other prior, concomitant and subsequent non-drug and drug treatments. These other non-drug treatments can be selected among the following classes or categories: surgical methods (surgical removal, cryosurgery, electrocauterization, conization, scraping, scooping (curettage), removal of lesions by chemical abrasion) and other procedures not specified. These referred drug treatments can be selected among the following classes or categories: biological response modifiers (imiquimod, resiquimod), HPV vaccines, photoactive compounds and other compounds not specified, which can be used alone or in combination or association with each other.

### Claim 16 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of primary and secondary cachexia, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with other pharmacologically active compounds in cancer treatment. Such pharmacologically active substances or compounds can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) and other compounds or substances not specified, which can be used alone or combined or associated with each other.

### Claim 17 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of primary and secondary cachexia, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance in cancer treatment. These other compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) and other compounds or substances not specified, which can be used alone or combined or associated with each other.

### Claim 18 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of primary and secondary cachexia, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with other pharmacologically active compounds or substances in the treatment of anorexia and cachexia. These other pharmacologically active compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: polyunsaturated fatty acids or Pufas (eicosaminopentoic acid—EPA, linoleic acid docosahexanenoic acid—DHA), aminoacids (arginine, glutamine), steroids (megestrol acetate), steroidal anti-inflammatory drugs (hydrocortisone, cortisone, corticosterone, dexamethasone, betamethasone, prednisolone, prednisone, methylprednisolone, budesonide, beclomethasone), derivatives of tetrahydrocannabinol (dronabinol), non-steroidal anti-inflammatory drugs (ibuprofen), enzyme inhibitors (eicosapentaenoic acid, hydrazine sulfate), hormones (melatonin, somatropin) and other compounds or substances not identified, which can be used alone or in combination or association with each other.

### Claim 19 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of primary and secondary cachexia, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance in the treatment of anorexia and cachexia. These other pharmacologically active compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: polyunsaturated fatty acids or Pufas (eicosaminopentoic acid—EPA, linoleic acid docosahexanenoic acid—DHA), aminoacids (arginine, glutamine), steroids (megestrol acetate), steroidal anti-inflammatory drugs (hydrocortisone, cortisone, corticosterone, dexamethasone, betamethasone, prednisolone, prednisone, methylprednisolone, budesonide, beclomethasone), derivatives of tetrahydrocannabinol (dronabinol), non-steroidal anti-inflammatory drugs (ibuprofen), enzyme inhibitors (eicosapentaenoic acid, hydrazine sulfate), hormones (melatonin, somatropin) and other compounds or substances not specified, which can be used alone or in combination or association with each other.

### Claim 20 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of primary and secondary cachexia, which shall include a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with other non-drug treatment in cancer treatment. These other non-drug treatments can be selected among the following classes or categories: surgical procedures (surgery, cryosurgery, electrocauterization, removal of lesions by chemical abrasion), radiotherapy (localized and systemic), and can be used alone or in combination or association with each other.

### Claim 21 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other pharmacologically active anticancer compound or substance. Such other pharmacologically active compounds or substances can be selected among the following classes or categories, cited as exemplification only, and by no means constituting an exhaustive list: alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) and other compounds or substances not specified, which can be used alone or combined or associated with each other.

### Claim 21 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with at least one other pharmacologically active compound or substance against immunosuppression and/or neutropenia. These pharmacologically active compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim), cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer and other compounds or substances not specified, which can be used alone or in combination or association with each other.

### Claim 22 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance in the treatment of cancer. These compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) and other compounds or substances not specified, which can be used alone or in combination or association with each other.

### Claim 23 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for use in the manufacture of new drugs and/or drug associations with at least one other pharmacologically active compound or substance in the treatment of immunosuppression and/or neutropenia. These other compounds or substances can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines) and other compounds or substances not specified, which can be used alone or in combination or association with each other.

### Claim 25 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component as a fixed component for prior, concomitant or subsequent use with at least one other non-drug anticancer treatment. These other non-drug treatments can be selected among the following classes or categories: surgical procedures (surgery, cryosurgery, electrocauterization, removal of lesions by chemical abrasion), radiotherapy (localized and systemic), which can be used alone or in combination or association with each other.

### Claim 26 (depends on 1)

The adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments according to claim 1, characterized as an association or combination of substances for the preventive, curative and palliative treatment of chronic systemic diseases such as cancer, and specifically in the treatment of immunosuppression and neutropenia, which shall include a specific biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use with other non-drug and drug anticancer treatments. These other non-drug treatments can be selected among the following classes or categories: surgical procedures (surgery, cryosurgery, electrocauterization, removal of lesions by chemical abrasion), radiotherapy (localized and systemic) and the other drug treatments can be selected among the following classes or categories, cited for exemplification only, and by no means constituting an exhaustive list: stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines) and other procedures not specified, which can be used alone or in association or combination with each other.
